5-aminosalicylic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer

Digestive Diseases and Sciences

Volumn 45, Issue 8, 2000, Pages 1578-1584

  Brown, W A ^a   Farmer, K C ^a   Skinner, S A ^a   Malcontenti Wilson, C ^a   Misajon, A ^a   O'Brien, P E ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

5 aminosalicylic acid; Apoptosis; Bromdeoxyuridine; Chemoprevention; Colorectal cancer; Olsalazine

Indexed keywords

1,2 DIMETHYLHYDRAZINE; ANTINEOPLASTIC AGENT; MESALAZINE; OLSALAZINE; AMINOSALICYLIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ANIMAL; CELL DIVISION; COLORECTAL TUMOR; DISEASE MODEL; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

AMINOSALICYLIC ACIDS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL DIVISION; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; MALE; MESALAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0033623301     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005517112039     Document Type: Article

References (40)

1. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat
2. Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis
3. Sulindac and indomethacin inhibit formation of aberant crypt foci in the colons of dimethyl hydrazine treated rats
4. Colorectal cancer risk, chronic illnesses, operations and medications: Case control results from the Melbourne colorectal cancer study
5. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis
6. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
7. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
8. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels
9. Sulindac inhibits colorectal tumor growth, but not prostaglandin synthesis in the rat
10. Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis
11. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: Comparison of intraluminal colonic concentrations, serum values and urinary excretion
12. Relative bioavailability of olsalazine from tablets and capsules: A drug targeted for local effect in the colon
13. Modulation of arachidonic acid metaboism by olsalazine and other aminosalicylates in leukocytes
14. Anaglesic ingestion and other factors preceding relapse in ulcerative colitis
15. Scavenger effect of sulfasalazine, 5-aminosalicylic acid and olsalazine on superoxide radical generation
16. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid
17. Modulation of human colonic arachidonic acid metabolism by sulfasalazine
18. The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis
19. Endogenous antioxidant status in neoplastic and adjacent tissues in 1,2-dimethylhydrazine-induced colon cancer in rats: Effects of olsalazine
20. Expression of 15-lipoxygenase-i in human colorectal cancer
21. Osalazine: A review of its pharmacodynamics and pharmacokinetic properties
22. Aberrant crypts: Putative preneoplastic loci in human colonic mucosa
23. The role of apoptosis in the modulation of colon carcinogenesis by dietary fat and by the organoselenium compound 1,4-Phenylenebis(methylene)selenocyanate
24. Regulation of cell number in the mammalian gastrointestinal tract: The importance of apoptosis
25. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion
26. Chemoprevention of colorectal cancer - The mechanism is multifactorial
27. Chemoprevention of colorectal cancer - A comparative study of efficacy and gastrotoxicity of NSAIDs
28. Specificity study to evaluate induction of aberrant crypts in murine colons
29. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
30. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
31. 1 to S phase
32. The colorectal tumor suppressor APC and its partners
33. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability
34. Cyclooxygenase-2 induction and transforming growth factor B growth inhibition in rat intestinal epithelial cells
35. Role for ceramide in cell cycle arrest
36. Bcl-2 interrupts the ceramide-mediated pathway of cell death
37. AOM-induced mouse colon tumors do not express full-length APC protein
38. B-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors
39. Mechanisms underlying nonsteroidal antiinflammatory drug mediated apoptosis
40. Selenium inhibition of 1,2-dimethylhydrazine-induced colon carcinogenesis